Bioventus Raises 2024 Guidance: Now Expects Net Sales Of $557M-$567M (Prior $535M-$550M) Vs. $542.767M Est., And Adj. EPS Of $0.36 To $0.42 (Prior $0.25 To $0.33) Vs. $0.28 Est.
Portfolio Pulse from Benzinga Newsdesk
Bioventus has raised its 2024 financial guidance, now expecting net sales of $557M-$567M and adjusted EPS of $0.36-$0.42, reflecting significant increases from previous estimates.
August 06, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bioventus has raised its 2024 financial guidance, now expecting net sales of $557M-$567M and adjusted EPS of $0.36-$0.42, reflecting significant increases from previous estimates.
The raised financial guidance indicates strong performance and positive future expectations, likely leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100